Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism

Brett Slajus, Yevgeniy Brailovsky, DO, Trung Phan, Iman Darwish, Jawed Fareed, PhD, Amir Darki, MD MSc

Blood (2019) 134 (Supplement_1): 2103.

https://doi.org/10.1182/blood-2019-127425

Published: 2019

Journal Articles

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Tyler Maclay, Joseph Vacca, Casey McComas, Alfredo Castro, Melinda Day, PhD, Kevin Mills, PhD

Blood (2018) 132 (Supplement 1): 3963.

https://doi.org/10.1182/blood-2018-99-119373

Published: 2018

Journal Articles

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Robert N Booher, PhD, Grzegorz S. Nowakowski, MD, Krish Patel, MD, Matthew A. Lunning, DO, Maria Elena S. Samson, B.S., Ruzanna Atoyan, MD, Anna W Ma, MS, Guang-Xin Xu, BS, Steven Dellarocca, B.S., Holly Modafferi, BS, Mylissa Borek, B.S., Zhidong Zhang, PhD, Jefferson Parker, PhD, Duncan Whitney, PhD, Hongwei Wang, MD, David P Tuck, MD, Anas Younes, MD

Blood (2018) 132 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2018-99-117383

Published: 2018

Journal Articles

Additive Effects of Decreased TfR1 and Ablated Erfe Improve Both Ineffective Erythropoiesis and Iron Overload in β-Thalassemic Mice

Marc Ruiz Martinez, PhD, Wenbin An, MD, Maria Feola, PhD, Tomas Ganz, MD PhD, Yelena Ginzburg, MD

Blood (2018) 132 (Supplement 1): 847.

https://doi.org/10.1182/blood-2018-99-119426

Published: 2018

Journal Articles

Zebrafish gata2 Orthologs Are Necessary but Not Sufficient for Developmental Hematopoiesis

Oscar Pena, BS, MSc, Jasmine Rowell, BS, MS, Hanna Lemmik, BS, Chianna Umamahesan, BS, MSc, Catherine Hockings, MBBChir, MA, FRCPath, MRCP, Elspeth Payne, MDPhDFRCPath

Blood (2017) 130 (Supplement 1): 3773.

https://doi.org/10.1182/blood.V130.Suppl_1.3773.3773

Published: 2017

Journal Articles

Atovaquone Demonstrates Single Agent Activity and an Additive Effect in Combination with Cytotoxic Chemotherapy (Cytarabine and Daunorubicin) in AML

Alexandra McLean Stevens, MD, Jaime Omar Munoz, Michael Krueger, Terzah M. Horton, MD PhD, Michele Redell, MD PhD

Blood (2017) 130 (Supplement 1): 3899.

https://doi.org/10.1182/blood.V130.Suppl_1.3899.3899

Published: 2017

Journal Articles

Myeloid Dendritic Cells Contribute to Hematopoietic Homeostasis

Jingzhu Zhang, BS, Daniel C. Link, MD, Teerawit Supakorndej, BS, Mahil Rao

Blood (2016) 128 (22): 30.

https://doi.org/10.1182/blood.V128.22.30.30

Published: 2016

Journal Articles

Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis

Sabrina Bossio, Laura De Stefano, Mariavaleria Pellicanò, PhD, Angela Palummo, Francesca Storino, Nadia Caruso, Giovanni Iaquinta, Giovanna Cutrona, PhD, Massimo Gentile, MD, Ernesto Vigna, Anna Grazia Recchia, PhD, Fortunato Morabito, MD, Antonino Neri, MD

Blood (2015) 126 (23): 1729.

https://doi.org/10.1182/blood.V126.23.1729.1729

Published: 2015

Journal Articles

The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway

Andrea Ghelli Luserna Di Rora, Ilaria Iacobucci, PhD, Neil Beeharry, Simona Soverini, Cristina Papayannidis, MD PhD, Giovanni Martinelli, MD PhD, Timothy J Yen

Blood (2015) 126 (23): 1276.

https://doi.org/10.1182/blood.V126.23.1276.1276

Published: 2015

Journal Articles

Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors

Sutapa Sinha, PhD, Justin Boysen, Michael Nelson, Charla Secreto, Steven L. Warner, PhD, David J. Bearss, PhD, Connie Lesnick, M.Sc, Tait D. Shanafelt, MD, Neil E. Kay, MD, Asish K Ghosh, PhD

Blood (2014) 124 (21): 1946.

https://doi.org/10.1182/blood.V124.21.1946.1946

Published: 2014

Journal Articles

Tumor Suppressors Btg1 and Btg2 Regulate B Lineage Commitment through Modulation of Ebf1 Activity

Esther Tijchon, MSc, Liesbeth van Emst, Bsc, Dorette van Ingen Schenau, MSc, Laurensia Yuniati, MSc, Jorn Havinga, MSc, Felice Tirone, PhD, Jean-Pierre Rouault, PhD, Peter M Hoogerbrugge, MD PhD, Frank N. van Leeuwen, PhD, Blanca Scheijen, PhD

Blood (2014) 124 (21): 4311.

https://doi.org/10.1182/blood.V124.21.4311.4311

Published: 2014

Journal Articles

Elevated EGR2 Expression Provides a Potential Link Between Cell Cycle Arrest and Induced Differentiation in Myeloid Progenitor Cells

Joshua B. Bland, BS, Jose R. Peralta, BS, William T. Tse, MD PhD

Blood (2014) 124 (21): 2733.

https://doi.org/10.1182/blood.V124.21.2733.2733

Published: 2014

Journal Articles

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Christina Krupka, Anna Jansen, Irène Lassmann, Jon Terrett, PhD, Dee Aud, Rachel Dusek, PhD, Arnima Bisht, PhD, Esteban Pombo-Villar, PhD, Christian Rohlff, PhD, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Torben Altmann, MD, Klaus H Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 987.

https://doi.org/10.1182/blood.V124.21.987.987

Published: 2014

Journal Articles

Relapse Kinetics in Acute Myeloid Leukemis Cases Encompassing More Than One Common Mutation: Towards a Unified Model

Hans Beier Ommen, MD PhD, Maria Hansen, MSc, PhD, Charlotte Guldborg Nyvold, MSc, PhD, Peter Hokland, MD DMSc

Blood (2014) 124 (21): 1055.

https://doi.org/10.1182/blood.V124.21.1055.1055

Published: 2014

Journal Articles

Stabilizing Factor VIIIa By Combining Mutations That Modulate Inter-Subunit Interactions and Proteolytic Inactivation

Hironao Wakabayashi, MD, PhD, Jennifer Wintermute, Philip J. Fay, PhD

Blood (2013) 122 (21): 3572.

https://doi.org/10.1182/blood.V122.21.3572.3572

Published: 2013

Journal Articles

Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia

Blood (2013) 122 (21): 1469.

https://doi.org/10.1182/blood.V122.21.1469.1469

Published: 2013

Journal Articles

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

Michael P. Rettig, PhD, Matthew Holt, Julie Prior, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 237.

https://doi.org/10.1182/blood.V122.21.237.237

Published: 2013

Journal Articles

Efficient Erythropoiesis From Human Embryonic Stem Cells Through Dimerization of Intracellular MPL.

William Sang Kim, B.S., Gautam G. Dravid, Ph.D, Yuhua Zhu, B.S., Chintan Parekh, MBBS, Qiming Deng, B.S., Roger P. Hollis, PhD, Timothy Lane, Ph.D, Donald B. Kohn, MD, Gay M. Crooks, MBBS

Blood (2012) 120 (21): 2291.

https://doi.org/10.1182/blood.V120.21.2291.2291

Published: 2012

Journal Articles

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Yuji Shimura, MD, Junya Kuroda, MD, PhD, Hisao Nagoshi, MD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Miki Kiyota, MD, Ryuko Nakayama, MD, Shinsuke Mizutani, MD, Yoshiaki Chinen, MD, Natsumi Sakamoto, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Masaki Ri, MD, PhD, Yukimasa Shiotsu, PhD, Shinsuke Iida, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 2945.

https://doi.org/10.1182/blood.V120.21.2945.2945

Published: 2012

NARROW

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Additive Effects of Decreased TfR1 and Ablated Erfe Improve Both Ineffective Erythropoiesis and Iron Overload in β-Thalassemic Mice

Zebrafish gata2 Orthologs Are Necessary but Not Sufficient for Developmental Hematopoiesis

Atovaquone Demonstrates Single Agent Activity and an Additive Effect in Combination with Cytotoxic Chemotherapy (Cytarabine and Daunorubicin) in AML

Myeloid Dendritic Cells Contribute to Hematopoietic Homeostasis

Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis

The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway

Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors

Tumor Suppressors Btg1 and Btg2 Regulate B Lineage Commitment through Modulation of Ebf1 Activity

Elevated EGR2 Expression Provides a Potential Link Between Cell Cycle Arrest and Induced Differentiation in Myeloid Progenitor Cells

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Relapse Kinetics in Acute Myeloid Leukemis Cases Encompassing More Than One Common Mutation: Towards a Unified Model

Stabilizing Factor VIIIa By Combining Mutations That Modulate Inter-Subunit Interactions and Proteolytic Inactivation

Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

Efficient Erythropoiesis From Human Embryonic Stem Cells Through Dimerization of Intracellular MPL.

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only